Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 249-253, May 2004

The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma

  • Justin Stebbing

      Affiliations

    • Medical Day Unit, Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
  • ,
  • Vanessa Marvin

      Affiliations

    • Pharmacy Department, Royal Surrey County Hospital, Guildford, Surrey, UK
  • ,
  • Mark Bower

      Affiliations

    • Medical Day Unit, Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-181-237-5054; fax: +44-181-746-8863

Abstract 

As we enter the third decade of the AIDS epidemic, it is apparent that a large number of cancers are more common in people with the human immunodeficiency virus type 1 (HIV). Non-Hodgkin’s lymphoma (NHL) remains the second most common tumour in such patients. At the onset of the epidemic, dose-intense combination regimens were used but these were quickly abandoned in favour of dose-modified strategies because of difficulties in tolerating aggressive chemotherapy in the presence of underlying immunosuppression. With the improvements in supportive care including more effective anti-retroviral therapies, colony-stimulating factors and prophylaxis against opportunistic infections, we are returning to the traditional chemotherapeutic approaches similar to those utilised in the non-HIV infected individual including infusional regimens. In this review, we discuss the evidence for choosing particular therapies in patients with AIDS-related NHL.

Keywords:  AIDS, HIV, Lymphoma, Non-Hogdkin’s lymphoma, Primary cerebral lymphoma, Chemotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(03)00216-0

doi:10.1016/j.ctrv.2003.12.004

Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 249-253, May 2004